The Dales Report’s Post

“The proposal of MDMA-AT, in its very presentation, is expected to be confounding. It is an unprecedented proposal. In addition, PTSD is confounding and not easily, nor scientifically, measurable. Therapy is confounding, and not easily or scientifically measurable. But the confounding nature of this study, this therapeutic work, and this diagnosis presentation, do not negate the results.” Southeast Coalition of Psychedelic Practitioners understands the arduous process Lykos and the FDA have begun. We support the continued efforts of this review to educate, reform, and define the process of MDMA-AT moving forward. Read the full statement below.

🎉 Who would have thought that ecstasy, once labeled as a party drug, could hold the key to treating PTSD? 🚀 Exciting strides have been made by the Multidisciplinary Association for Psychedelic Studies (MAPS) in their groundbreaking journey toward making MDMA the first FDA-approved psychedelic drug. 👥 MAPS CEO, Amy Emerson, states, "This is a potential new option for adults living with PTSD, a patient group that has experienced little innovation in decades." 🌟 MAPS has submitted the first-ever FDA New Drug Application (NDA) for MDMA-assisted therapy for PTSD, backed by a successful phase three clinical trial where 86.5% of participants achieved a clinically meaningful benefit. Check out the full article in the comments! #mentalhealthrevolution #mdma #ptsd

In case you missed it: The Multidisciplinary Association for Psychedelic Studies (MAPS) has further confirmed their previous findings suggesting that MDMA, when administered in the proper clinical setting, can significantly reduce symptoms of PTSD. Their newest study also demonstrated MDMA's effectiveness in treating patients from diverse racial and ethnic backgrounds, with around half of the study's participants identiying as racially or ethnically diverse. This new data provides yet another stepping stone towards FDA approval for MDMA, as MAPS now works towards compiling findings across its research efforts to file an application later this year. Learn more about MAPS' exciting new findings and the future of MDMA: https://lnkd.in/eE6XuAjr #mdma #ptsd #mdmaforptsd #maps #psychedelictherapy #psychedelicresearch #psychedelicmedicine

Major announcement: As of last week, the FDA has accepted and granted priority review the first New Drug Application for MDMA to be used together with psychological intervention, including psychotherapy (talk therapy) to treat PTSD via Lykos Therapeutics. According to a statement by Lykos, “If approved, this would be the first MDMA-assisted therapy and psychedelic-assisted therapy available to treat individuals with PTSD in the U.S.” Jayne Gumpel, LCSW here at Relationship Resources has previously completed training with MAPS for MDMA assisted psychotherapy, and we hope with this possible approval to incorporate this form of medicine into our future retreats! #PsychedelicTherapy #PsychedelicResearch #PsychedelicEducation #MassMentalHealth #PsychedelicScience

Psychedelic assisted therapies (PAT) for conditions like depression, PTSD, and substance use disorders are all over the internet and in the media spotlight. But are they right for your patients? And how would you offer them? This session at #NPInstitute2024 will discuss the model of PAT as it exists right now in the research world, examine the evidence and neuroscience behind the studies, and discuss how and when these treatments might be a part of your clinical practice. Don't wait to register - rates increase Friday! https://bit.ly/3Sd1bfw

📈 Universities in other countries are studying MDMA therapy for PTSD and finding success! The Universiteit van Amsterdam published this journal article:  MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. This journal submission has all the research language you could ask for!  If you are like me and want the summary - here you go! "These data indicate that, compared with manualized therapy with inactive placebo, MDMA-assisted therapy is highly efficacious in individuals with severe PTSD, and treatment is safe and well-tolerated, even in those with comorbidities. We conclude that MDMA-assisted therapy represents a potential breakthrough treatment that merits expedited clinical evaluation." If you love statistics - the full article is in the comments!

MDMA FOR PTSD - 2nd POSITIVE PHASE III STUDY! Big news, important news. Published in Nature Medicine. A brief video to introduce this big news and a link to the full article is here - (thanks Andrew for alerting me to this gem) - https://lnkd.in/gWCveA6H

In September 2023, over 100 new psychedelic research articles were published. I combed through them and put the 25 most exciting studies in this recap 👇 The second Phase III study from MAPS was published, showing that more than 2/3rd of those treated with MDMA-assisted psychotherapy no longer met DSM-5 criteria for PTSD. With 104 participants, the study complements the first Phase III study and marks the transition to the next step in psychedelic research, the FDA approval process. Next to MAPS' landmark study, we were also treated to the largest prospective survey of people using psychedelics outside the clinical setting. In settings outside the lab, respondents generally found benefits such as reduced alcohol misuse, better emotional regulation, and improved spiritual well-being. The data could serve as a counterpoint towards recent negative news around self-experimentation with psychedelics. September was another productive month for psychedelic research, with 25 articles (and full summaries for paying members) added to the database (nearing 2000 articles). In this recap, we also cover exciting news about psychedelics and our immune system, the surprising similarity between MDMA and methamphetamine, and how to prevent history from repeating itself. Continue reading on Blossom 👇 #psychedelicresearch #psychedelics #MDMA

The field of psychiatry is FINALLY focusing on the biological aspect of these complex medical conditions

Psychedelic-based therapy shows great promise in treating disorders ranging from depression and anxiety to chronic pain and PTSD. This is an informative podcast with United States Marine Corps veteran Juliana Mercer, Michael Flaum, MD, and Candida Maurer, Ph.D., discussing the effectiveness and healing breakthrough possible through psilocybin and MDMA-assisted therapy. They delve into the science behind these treatments and share personal stories of transformation. #veteranshealth #pstd #psychedelicscience #psychedelics #mentalhealth #healthequity